| International FP-007 |
| Clinical Presentation and Treatment Outcomes of Primary Ocular Adnexal MALT Lymphoma in Thailand |
| Department of Ophthalmology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand(1)
Department of Medicine, Division of Hematology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand (2)
Department of Ophthalmology, Faculty of Medicine, King Chulalongkorn Memorial Hospital, Bangkok, Thailand(3)
Department of Medicine, Division of Hematology, Faculty of Medicine, King Chulalongkorn Memorial Hospital, Bangkok, Thailand(4)
|
| Kasem Seresirikachorn(1), Lalita Norasetthada(2), Sakarin Ausayakhun(1), Atitaya Apivatthakakul(1), Damrong Wiwatwongwana(1), Sirima Tangchittam(3), Vannakorn Pruksakorn(3), Kitsada Wudhikarn(4) |
|
Purpose : To assess the characteristics and treatment outcomes of patients with primary ocular adnexal MALT lymphoma (POAML) in Thailand.
Methods : A retrospective, multicenter study included all patients who were diagnosed with POAML between January 2004 and December 2016 from Chiang Mai University Hospital and King Chulalongkorn Memorial Hospital, Thailand.
Results : Of 146 ocular lymphoma, 121 patients (82%) were diagnosed with POAML. Among patients with POAML, the median age was 58 (range, 22-86) years old with 53% of them were female. Orbital mass (71%) was the most common presenting symptoms. The common sites of origin were orbit (46.3%) and lacrimal gland (35%). About 60% the patients presented with stage I disease. Radiotherapy was the primary treatment for limited stage diseases. The overall response rate was 100%, with a complete response rate of 80%. The 5-year progression free survival and overall survival were 70% and 94%, respectively. Radiotherapy based treatment was independently associated with a better PFS in patients with limited stage of disease [HR 0.26; 95%CI 0.09-0.74, P=0.012].
Conclusion : POAML was the most common subtype of lymphoma involving eyes. Radiotherapy play a significant role in disease control, contributing to an improved long-term outcome in limited-stage POAML patients.
|
| |